Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5287-5300

  Yuan, Rongfa ^a,b   Wang, Kai ^a,b   Hu, Junwen ^a   Yan, Chen ^a   Li, Ming ^a   Yu, Xin ^a,b   Liu, Xiuxia ^a,c   Lei, Jun ^a,b   Guo, Wuhua ^a   Wu, Linquan ^a,b   Hong, Kui ^c   Shao, Jianghua ^a,b,c  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Province Engineering Research Center of Hepatobiliary Disease   (China)

^c Jiangxi Province Key Laboratory of Molecular Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BETA CATENIN; HOMEODOMAIN PROTEIN; HOXB9 PROTEIN, HUMAN; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UBD PROTEIN, HUMAN; UBIQUITIN;

ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS; TRANSFECTION; UBIQUITINS;

EID: 84907484229     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0284     Document Type: Article

References (50)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
2. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196-202.
3. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;51:459-62.
4. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009;10:659-71.
5. Raasi S, Schmidtke G, Groettrup M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 2001;276:35334-43.
6. Ren J, Wang Y, Gao Y, Mehta SB, Lee CG. FAT10 mediates the effect of TNF-alpha in inducing chromosomal instability. J Cell Sci 2011;124:3665-75.
7. Merbl Y, Refour P, Patel H, Springer M, Kirschner MW. Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell 2013;152:1160-72.
8. Ji F, Jin X, Jiao CH, Xu QW, Wang ZW, Chen YL. FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J Gastroenterol 2009;15:2228-33.
9. Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, et al. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008;27:6068-74.
10. Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003;22:2592-603.
11. Sun GH, Liu YD, Yu G, Li N, Sun X, Yang J. Increased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 2014;35:5167-71.
12. Yuan J, Tu Y, Mao X, He S, Wang L, Fu G, et al. Increased expression of FAT10 is correlated with progression and prognosis of human glioma. Pathol Oncol Res 2012;18:833-9.
13. Oliva J, Bardag-Gorce F, French BA, Li J, McPhaul L, Amidi F, et al. Fat10 is an epigenetic marker for liver preneoplasia in a drugprimed mouse model of tumorigenesis. Exp Mol Pathol 2008;84:102-12.
14. Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, et al. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3beta pathway. Oncogene 2014;33:909-20.
15. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777-85.
16. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A 2010;107:1100-5.
17. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;138:51-62.
18. Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, et al. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol 2008;28:2732-44.
19. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-51.
20. Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH, Tsai FJ, et al. Beta-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol Rep 2011;26:415-22.
21. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999;9:15-21.
22. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
23. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
24. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 2005;25:3483-91.
25. Schmidtke G, Kalveram B, Groettrup M. Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 2009;583:591-4.
26. Liu T, Yu X, Li G, Yuan R, Wang Q, Tang P, et al. Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells. Exp Cell Res 2012;318:1994-2003.
27. Schmidtke G, Aichem A, Groettrup M. FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta 2014;1843:97-102.
28. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
29. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of betacatenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
30. Fan W, Cai W, Parimoo S, Schwarz DC, Lennon GG, Weissman SM. Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics 1996;44:97-103.
31. Lim CB, Zhang D, Lee CG. FAT10, a gene up-regulated in various cancers, is cell-cycle regulated. Cell Div 2006;1:20.
32. Qing X, French BA, Oliva J, French SW. Increased expression of FAT10 in colon benign, premalignant and malignant epithelial neoplasms. Exp Mol Pathol 2011;90:51-4.
33. Peng X, Shao J, Shen Y, Zhou Y, Cao Q, Hu J, et al. FAT10 protects cardiac myocytes against apoptosis. J Mol Cell Cardiol 2013;59:1-10.
34. Gao Y, ThengSS, Zhuo J, Teo WB, Ren J, Lee CG. FAT10, anubiquitinlike protein, confers malignant properties in non-tumorigenic and tumorigenic cells. Carcinogenesis 2014;35:923-34.
35. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A 2000;97:12776-81.
36. Liu YC, Pan J, Zhang C, Fan W, Collinge M, Bender JR, et al. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc Natl Acad Sci U S A 1999;96:4313-8.
37. Schmidtke G, Kalveram B, Weber E, Bochtler P, Lukasiak S, Hipp MS, et al. The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem 2006;281:20045-54.
38. Kalveram B, Schmidtke G, Groettrup M. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci 2008;121:4079-88.
39. Yu X, Liu X, Liu T, Hong K, Lei J, Yuan R, et al. Identification of a novel binding protein of FAT10: eukaryotic translation elongation factor 1A1. Dig Dis Sci 2012;57:2347-54.
40. Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 1998;8:95-102.
41. Shackelford J, Pagano JS. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination. Mol Cell Biol 2004;24:5089-93.
42. Walden H, Podgorski MS, Schulman BA. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature 2003;422:330-4.
43. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005;6:599-609.
44. Wang J, Feng XH, Schwartz RJ. SUMO-1 modification activated GATA4-dependent cardiogenic gene activity. J Biol Chem 2004;279:49091-8.
45. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 2006;281:3989-94.
46. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem 2006;281:4334-8.
47. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006;66:921-8.
48. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, et al. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 2004;324:394-400.
49. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, et al. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 2006;8:1424-31.
50. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999;18:6462-71.